Recently, Kikuchi et al. found that the administration of lenalidomide prevented the LPS-triggered activation of multiple myeloma cells by targeting RP105 (Kikuchi and Furukawa, 2020). The gene discussed is CD180; the disease is plasma cell myeloma.